Lifetime risk of heart failure and trends in incidence rates among individuals with type 2 diabetes between 1995 and 2018

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 839 KB, PDF-dokument

BACKGROUND: There are limited data on the lifetime risk of heart failure (HF) in people with type 2 diabetes and how incidence has changed over time. We estimated the cumulative incidence and incidence rates of HF among Danish adults with type 2 diabetes between 1995 and 2018 using nationwide data. METHODS AND RESULTS: In total, 398 422 patients (49% women) with type 2 diabetes were identified. During follow-up, 36 400 (9%) were diagnosed with HF and 121 459 (30%) were censored due to death. Using the Aalen-Johansen estimators, accounting for the risk of death, the estimated residual lifetime risk of HF at age 50 years was calculated as 24% (95% CI 22%– 27%) in women and 27% (25%–28%) in men. During the observational period, the proportion of patients treated with statins, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, and metformin increased from <30% to >60%. Similarly, the annual incidence rates of HF decreased significantly, with declines being greater in older versus younger individuals (5% versus 2% in age >50 versus ≤50 years, respectively; P<0.0001) and in women versus men (5% versus 4%, P=0.02), but similar in patients with and without IHD (4% versus 4%, P=0.53). CONCLUSIONS: The current lifetime risk of HF in type 2 diabetes approximates 1 in 4 for men and women. Paralleled by an increase in use of evidence-based pharmacotherapy over the past decades, the risk of developing HF has declined across several subgroups and regardless of underlying IHD, suggesting that optimal diabetes treatment can mitigate HF risk.

OriginalsprogEngelsk
Artikelnummere021230
TidsskriftJournal of the American Heart Association
Vol/bind10
Udgave nummer21
ISSN2047-9980
DOI
StatusUdgivet - 2021

Bibliografisk note

Funding Information:
Brian Schwartz was supported by the National Institute of Health 1R38HL143584. Vasan S Ramachandran was supported in part by the Evans Medical Foundation and the Jay and Louis Coffman Endowment from the Department of Medicine, Boston University School of Medicine.

Funding Information:
Morten Schou has received lecture fees from Bohringer Ingelheim, AstraZeneca, and Novo Nordisk, Lars Køber reports lecture fees from Novartis, BMS, and AstraZeneca, and Christian Torp-Pedersen has received study funding from Bayer and Novo Nordisk, all unrelated to the present work. The remaining authors have no disclosures to report.

Publisher Copyright:
© 2021 The Authors.

ID: 301820680